Comparison of Maturation Rates of Oocytes Collected From Patients with Different Ovarian Reserves Undergoing IVF at an IVF Clinic
Research Article
DOI:
https://doi.org/10.5281/zenodo.20836215Keywords:
Anti-mullerian Hormone, In Vitro Fertilization, Ovarian Reserve, MII oocyteAbstract
Objective: To compare the maturation rates of oocytes collected in patients with low, normal, and high ovarian reserve according to the anti-mullerian hormone (AMH) level and antral follicule count (AFC), where in-vitro fertizition (IVF) was performed in the in-vitro fertilization clinic of our faculty of medicine between 2017-2022.
Methods: This retrospective study included women aged between 23 and 45 who underwent IVF treatment between 2017 and 2022. Patients were divided to three groups. Group 1: low; group 2: normal; group 3: high ovarian reserve, according to the ovarian reserve. Age, AFC, AMH values, body mass index, oocyte maturation rate, total oocyte counts, FSH, LH, TSH and estradiol levels were recorded.
Results: 22% of the patients had low, 46.1% normal, and 31.9% had high ovarian reserve. There was a statistically significant difference among the groups according to the age, FSH, LH and E2 levels, drug dose used, number of oocytes collected (COC) and number of MII oocytes (p<0.001). Ovitrelle was used in 81.6% of the participants, Gonapeptly in 17.8% and Ovitrelle+Gonapeptly in 0.6% of the participants, for oocyte maturation. The mean total MII oocyte count were higher in the gonapeptly used group. It was observed that 67.3% of MII oocyte in group 1 women, 66.9% of MII oocyte in group 2 women, and 67.3% of MII oocyte in group 3 women. There was a similar oocyte maturation rate among the groups.
Conclusion: There was a relationship between ovarian reserve and COC, but maturation rates were similar among the groups. This suggests that MII oocytes can be obtained with individualized treatments, regardless of ovarian reserve.
References
1. Masoumi SZ, Parsa P, Darvish N, Mokhtari S, Yavangi M, Roshanaei G. An epidemiologic survey on the causes of infertility in patients referred to infertility center in Fatemieh Hospital in Hamadan. Iran J Reprod Med. 2015;13(8):513–6.
2. Nwajiaku L, Mbachu I, Ikeako L. Prevalence, Clinical Pattern and Major Causes of Male Infertility in Nnewi, South East Nigeria: A Five Year Review. Afrimedic J. 2012;3(2):16–9.
3. Hipp H, Crawford S, Kawwass JF, Chang J, Kissin DM, Jamieson DJ. First trimester pregnancy loss after fresh and frozen in vitro fertilization cycles. Fertil Steril [Internet]. 2016 Mar;105(3):722–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028215020889
4. Sunderam S, Kissin DM, Zhang Y, Folger SG, Boulet SL, Warner L, et al. Assisted Reproductive Technology Surveillance — United States, 2016. MMWR Surveill Summ [Internet]. 2019 Apr 26;68(4):1–23. Available from: http://www.cdc.gov/mmwr/volumes/68/ss/ss6804a1.htm?s_cid=ss6804a1_w
5. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys. Low N, editor. PLoS Med [Internet]. 2012 Dec 18;9(12):e1001356. Available from: https://dx.plos.org/10.1371/journal.pmed.1001356
6. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod [Internet]. 2011 Jul 1;26(7):1616–24. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/der092
7. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril [Internet]. 2016 Jun;105(6):1452–3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028216000893
8. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers [Internet]. 2016;2016:1–9. Available from: http://www.hindawi.com/journals/dm/2016/5246217/
9. Bentzen JG, Forman JL, Johannsen TH, Pinborg A, Larsen EC, Andersen AN. Ovarian Antral Follicle Subclasses and Anti-Müllerian Hormone During Normal Reproductive Aging. J Clin Endocrinol Metab [Internet]. 2013 Apr 1;98(4):1602–11. Available from: https://academic.oup.com/jcem/article/98/4/1602/2536942
10. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause. Vitzthum VJ, editor. PLoS One [Internet]. 2011 Jul 15;6(7):e22024. Available from: https://dx.plos.org/10.1371/journal.pone.0022024
11. Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJC, Broekmans FJ, et al. Serum Anti-Müllerian Hormone Levels in Healthy Females: A Nomogram Ranging from Infancy to Adulthood. J Clin Endocrinol Metab [Internet]. 2012 Dec 1;97(12):4650–5. Available from: https://academic.oup.com/jcem/article/97/12/4650/2536586
12. Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod [Internet]. 2016 Jan 2;dev316. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/dev316
13. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IAJ, de Vet A, Themmen APN, et al. Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. J Clin Endocrinol Metab [Internet]. 2011 Aug;96(8):2532–9. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2010-2776
14. Frattarelli JL, Lauria-Costab DF, Miller BT, Bergh PA, Scott RT. Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil Steril [Internet]. 2000 Sep;74(3):512–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028200007081
15. Yates AP, Rustamov O, Roberts SA, Lim HYN, Pemberton PW, Smith A, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod [Internet]. 2011 Sep 1;26(9):2353–62. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/der182
16. Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril [Internet]. 2011 Apr;95(5):1655–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S001502821100029X
17. Ren Y, Wang Y, Fu M, Zhang Q, Shen H, Han H, et al. Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve. Curr Med Sci [Internet]. 2022 Oct 23;42(5):1066–70. Available from: https://link.springer.com/10.1007/s11596-022-2608-2
18. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update [Internet]. 2014 Jan 1;20(1):124–40. Available from: https://academic.oup.com/humupd/article-lookup/doi/10.1093/humupd/dmt037
19. Bala J. Chemotherapy: Impact on Anti- Müllerian Hormone Levels in Breast Carcinoma. J Clin Diagnostic Res [Internet]. 2016; Available from: http://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2016&volume=10&issue=2&page=BC19&issn=0973-709x&id=7328
20. Martinez F, Barri PN, Coroleu B, Tur R, Sorsa-Leslie T, Harris WJ, et al. Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles. Hum Reprod [Internet]. 2002 Mar 1;17(3):634–40. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/17.3.634
21. Firns S, Cruzat VF, Keane KN, Joesbury KA, Lee AH, Newsholme P, et al. The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data. Reprod Biol Endocrinol [Internet]. 2015 Dec 16;13(1):134. Available from: http://www.rbej.com/content/13/1/134
22. Moy V, Jindal S, Lieman H, Buyuk E. Obesity adversely affects serum anti-müllerian hormone (AMH) levels in Caucasian women. J Assist Reprod Genet [Internet]. 2015 Sep 21;32(9):1305–11. Available from: http://link.springer.com/10.1007/s10815-015-0538-7
23. Dólleman M, Verschuren WMM, Eijkemans MJC, Dollé MET, Jansen EHJM, Broekmans FJM, et al. Reproductive and Lifestyle Determinants of Anti-Müllerian Hormone in a Large Population-based Study. J Clin Endocrinol Metab [Internet]. 2013 May 1;98(5):2106–15. Available from: https://academic.oup.com/jcem/article/98/5/2106/2537071
24. Shapiro AJ, Darmon SK, Barad DH, Gleicher N, Kushnir VA. Vitamin D levels are not associated with ovarian reserve in a group of infertile women with a high prevalance of diminished ovarian reserve. Fertil Steril [Internet]. 2018 Sep;110(4):761-766.e1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028218304060
25. Dennis N, Houghton L, Pankhurst M, Harper M, McLennan I. Acute Supplementation with High Dose Vitamin D3 Increases Serum Anti-Müllerian Hormone in Young Women. Nutrients [Internet]. 2017 Jul 8;9(7):719. Available from: https://www.mdpi.com/2072-6643/9/7/719
26. Merhi ZO, Seifer DB, Weedon J, Adeyemi O, Holman S, Anastos K, et al. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women’s Interagency HIV Study. Fertil Steril [Internet]. 2012 Jul;98(1):228–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028212003676
27. Patrizio P, Silber S. Improving IVF: is there a limit to our ability to manipulate human biology? J Assist Reprod Genet [Internet]. 2017 Jan 28;34(1):7–9. Available from: http://link.springer.com/10.1007/s10815-016-0828-8
28. Arroyo A, Kim B, Yeh J. Luteinizing Hormone Action in Human Oocyte Maturation and Quality: Signaling Pathways, Regulation, and Clinical Impact. Reprod Sci [Internet]. 2020 Jun 6;27(6):1223–52. Available from: http://link.springer.com/10.1007/s43032-019-00137-x
29. Downs SM. Regulation of the G2/M transition in rodent oocytes. Mol Reprod Dev [Internet]. 2010 Jul 23;77(7):566–85. Available from: https://onlinelibrary.wiley.com/doi/10.1002/mrd.21175
30. Coticchio G, Cimadomo D, De Vos M, Ebner T, Esbert M, Escribá MJ, et al. To rescue or not to rescue immature oocytes: prospects and challenges. Fertil Steril [Internet]. 2025 May;123(5):749–58. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028225001475
31. Spits C, Guzman L, Mertzanidou A, Jacobs K, Ortega-Hrepich C, Gilchrist RB, et al. Chromosome constitution of human embryos generated after in vitro maturation including 3-isobutyl-1-methylxanthine in the oocyte collection medium. Hum Reprod [Internet]. 2015 Mar;30(3):653–63. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/deu329
32. Madkour A, Bouamoud N, Kaarouch I, Louanjli N, Saadani B, Assou S, et al. Follicular fluid and supernatant from cultured cumulus-granulosa cells improve in vitro maturation in patients with polycystic ovarian syndrome. Fertil Steril [Internet]. 2018 Sep;110(4):710–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028218303923
33. Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod [Internet]. 2013 Oct 1;28(10):2728–34. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/det303
34. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod [Internet]. 2011 Jul;26(7):1768–74. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/der106
35. van der Gaast M, Eijkemans M, van der Net J, de Boer E, Burger C, van Leeuwen F, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online [Internet]. 2006 Jan;13(4):476–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1472648310606335
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Medica Ruha
This work is licensed under a Creative Commons Attribution 4.0 International License.
